NSRGY - Red Light For Seres Therapeutics But Not A Stop Light For Me
- Seeking Alpha’s metrics give Seres Therapeutics a “Very Bearish” quant rating.
- I agree with Seeking Alpha’s assessment based on its performance, but there are reasons why this might change.
- Nestle is a strong supporter of Seres and recently injected $175 million to acquire further rights to its SER-109 C.difficile product and rights to market other products in North America.
- Seres announced a manufacturing partnership for SER-109 with Swiss contract development and manufacturing company Bacthera.
- The likelihood that SER-109 gets FDA designation as the first microbiomics product seems high and relatively near term.
For further details see:
Red Light For Seres Therapeutics, But Not A Stop Light For Me